Hormonal
Obese humans have elevated serum OB protein concentrations that correlate with body fat percentage, suggesting that human obesity is not caused by a deficiency in OB protein but potentially by reduced brain sensitivity to it.
This paper indicates that obese individuals typically have higher levels of OB protein (leptin) than lean individuals. This suggests that obesity is not caused by a lack of this hormone, but potentially by the body's reduced ability to respond to it or transport it to the brain.
When obese subjects were compared to lean individuals, it was observed that the serum OB protein concentrations were higher in obese individuals; and OB protein concentrations increased with increasing percent body fat
Why this rating
Based on multiple human studies cited (Considine et al., 1996; others), showing consistent correlation between body fat and OB protein levels.
Source
The OB Protein (Leptin) Pathway - A Link Between Adipose Tissue Mass and Central Neural Networks
L. Arthur Campfield et al. · Hormone and Metabolic Research · 1996
DOI 10.1055/s-2007-979867
More from this paper
- Central administration of recombinant OB protein (leptin) reduces food intake and body weight in lean and ob/ob mice, demonstrating that the protein acts on central neural networks to regulate energy balance.Good
- Reduced entry of OB protein into the brain, potentially due to high plasma concentrations saturating the transport system, may be a mechanism for reduced sensitivity of the OB protein pathway in obese individuals.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →